Sermorelin dosage: the clinical history vs. the modern anti-aging claim

“Sermorelin dosage” is one of the most searched questions about this peptide, and the honest answer has two halves that are usually collapsed into one. Sermorelin — GHRH 1-29, the active fragment of growth-hormone-releasing hormone — was once an approved prescription drug (marketed as Geref) with genuine, documented, label-defined dosing for two specific clinical jobs. Today, almost all sermorelin is sold through compounding and “research” channels for off-label “anti-aging” and GH-optimization, where no standardized, outcome-validated dose exists. This page describes the first world as history and is explicit that the second is not a protocol.

The clinical-era dosing that actually existed

In its approved-drug era, sermorelin had two well-characterized uses, each with its own dosing logic. The first was diagnostic: a single, weight-based intravenous bolus of GHRH 1-29 (on the order of one microgram per kilogram) was used as a provocative stimulation test, measuring how much growth hormone the pituitary released in response.^[1] Its pharmacokinetics — a short half-life and a prompt, measurable GH pulse — were formally studied in healthy subjects, which is what made it usable as a calibrated test rather than guesswork.^[2] This single-dose diagnostic role was a recognized part of evaluating short stature and suspected GH deficiency.^[3]

The second use was therapeutic, and it is the one most relevant to anyone reasoning about “a sermorelin dose.” In children with growth-hormone deficiency, sermorelin was given as a daily subcutaneous injection, dosed per the drug label and trial protocols, with the goal of coaxing the child’s own pituitary to release GH and accelerate growth. A multicenter study (the Geref International Study Group) showed that once-daily subcutaneous GHRH therapy accelerated growth in GH-deficient children over the first year.^[4] Contemporary reviews summarized this defined pediatric dosing and the diagnostic test as the established, evidence-backed uses of the molecule.^[3] That is the key point: where sermorelin had a real dose, that dose was tied to a diagnosis, a label, a trial protocol, and a measured outcome.

Why the modern “anti-aging” dose is a different thing entirely

The dosing you see circulated today — nightly subcutaneous injections taken by healthy adults to “optimize” growth hormone, lean mass, sleep or aging — is not a continuation of that clinical record. It is a separate practice that borrows the molecule’s name and its mechanism while leaving behind everything that made the original dosing trustworthy. There is no FDA-approved sermorelin product for these uses, no label that defines a dose for them, and — critically — no body of randomized outcome trials showing that any particular adult “anti-aging” dose produces the benefits it is sold for. Even the most favorable framing of sermorelin in adults — as a possible approach to adult-onset GH insufficiency — was presented as a question and a rationale, not as an established, dose-validated anti-aging therapy.^[5]

That gap matters because raising a hormone level is not the same as improving health. A dose can reliably move GH or IGF-1 and still have no demonstrated effect on the things people actually want, and the broader evidence for sermorelin’s adult outcomes remains thin — we walk through it in our sermorelin evidence review. So a number on a compounding-pharmacy instruction sheet is not the same kind of object as a number in a drug label: the first is a convention, the second was earned through trials.

The supply problem sits on top of the dosing problem

There is a second, more practical reason this page is not a how-to. When sermorelin is dispensed outside the approved-drug system, the concentration, purity and identity of what is in the vial are not guaranteed to pharmaceutical standards. A “dose” is only meaningful if you actually know how much active, correctly folded peptide you are administering — and in research-channel and some compounded products, that assurance is exactly what is missing. Pairing an unvalidated dose with an unverified product compounds the uncertainty rather than canceling it. The plausible adverse effects of stimulating this axis are covered separately in our sermorelin side effects overview.

The honest bottom line

Sermorelin genuinely had a dose — two, in fact: a single weight-based diagnostic bolus and a daily, label-defined pediatric therapy, both anchored to real trials and real endpoints. Those belong to history and to specialist medicine, not to a self-administered anti-aging routine. The modern “anti-aging” dosing that dominates search results has no comparable foundation: no approval, no outcome trials, and no guarantee of what is in the vial. Describing the documented clinical dosing is fair; presenting today’s popular protocol as evidence-based would not be. If you are weighing sermorelin for an off-label use, the appropriate next step is a conversation with a qualified clinician — not a dose copied from a forum.